Loading...

Menlo Therapeutics

Nasdaq:MNLO
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MNLO
Nasdaq
$169M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Menlo Therapeutics has significant price volatility in the past 3 months.
MNLO Share Price and Events
7 Day Returns
-0.3%
NasdaqGS:MNLO
-3.4%
US Pharmaceuticals
-0.1%
US Market
1 Year Returns
-8.2%
NasdaqGS:MNLO
6.9%
US Pharmaceuticals
7.6%
US Market
MNLO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Menlo Therapeutics (MNLO) -0.3% -6% 32.5% -8.2% - -
US Pharmaceuticals -3.4% -5.1% -1.1% 6.9% 6.3% 13.3%
US Market -0.1% 3.7% 10.2% 7.6% 38.1% 46.4%
1 Year Return vs Industry and Market
  • MNLO underperformed the Pharmaceuticals industry which returned 6.9% over the past year.
  • MNLO underperformed the Market in United States of America which returned 7.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

MNLO Value

 Is Menlo Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Menlo Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $7.26.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Menlo Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Menlo Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:MNLO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.37
NasdaqGS:MNLO Share Price ** NasdaqGS (2019-04-23) in USD $7.26
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.77x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.03x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Menlo Therapeutics.

NasdaqGS:MNLO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:MNLO Share Price ÷ EPS (both in USD)

= 7.26 ÷ -2.37

-3.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Menlo Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Menlo Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Menlo Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:MNLO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-1.3%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.49x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Menlo Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Menlo Therapeutics's assets?
Raw Data
NasdaqGS:MNLO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $5.61
NasdaqGS:MNLO Share Price * NasdaqGS (2019-04-23) in USD $7.26
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 182 Publicly-Listed Pharmaceuticals Companies 3.49x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqGS:MNLO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:MNLO Share Price ÷ Book Value per Share (both in USD)

= 7.26 ÷ 5.61

1.29x

* Primary Listing of Menlo Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Menlo Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Menlo Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Menlo Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MNLO Future Performance

 How is Menlo Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Menlo Therapeutics expected to grow at an attractive rate?
  • Unable to compare Menlo Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Menlo Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Menlo Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:MNLO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:MNLO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -1.3%
NasdaqGS:MNLO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 52.9%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:MNLO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:MNLO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 60 -41 -85 4
2022-12-31 24 -67 -67 5
2021-12-31 2 -80 -74 5
2020-12-31 0 -70 -71 5
2019-12-31 0 -76 -81 5
NasdaqGS:MNLO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 11 -53 -51
2018-09-30 13 -46 -43
2018-06-30 14 -47 -38
2018-03-31 5 -34 -36
2017-12-31 5 -28 -29
2017-09-30 2 -23 -25
2017-06-30 2 -4 -20
2017-03-31 1 -6 -17
2016-12-31 1 -2 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Menlo Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Menlo Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:MNLO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Menlo Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:MNLO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.30 -2.06 -2.53 2.00
2022-12-31 -1.99 -1.48 -2.73 4.00
2021-12-31 -2.24 -1.70 -2.83 4.00
2020-12-31 -2.51 -1.94 -2.88 4.00
2019-12-31 -3.39 -3.18 -3.57 4.00
NasdaqGS:MNLO Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.37
2018-09-30 -2.51
2018-06-30 -3.03
2018-03-31 -4.40
2017-12-31 -5.69
2017-09-30 -4.84
2017-06-30 -3.93
2017-03-31 -3.31
2016-12-31 -2.82

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Menlo Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Menlo Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Menlo Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MNLO Past Performance

  How has Menlo Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Menlo Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Menlo Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Menlo Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Menlo Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Menlo Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Menlo Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:MNLO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 10.64 -51.45 12.19
2018-09-30 13.42 -43.13 10.53
2018-06-30 14.32 -38.45 8.73
2018-03-31 4.63 -36.26 6.85
2017-12-31 4.58 -29.08 5.17
2017-09-30 2.26 -24.64 4.76
2017-06-30 1.57 -19.86 4.37
2017-03-31 1.12 -16.63 3.96
2016-12-31 0.67 -14.07 3.75
2015-12-31 -4.61 1.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Menlo Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Menlo Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Menlo Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Menlo Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Menlo Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MNLO Health

 How is Menlo Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Menlo Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Menlo Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Menlo Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Menlo Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Menlo Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Menlo Therapeutics Company Filings, last reported 3 months ago.

NasdaqGS:MNLO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 130.38 0.00 136.25
2018-09-30 146.88 0.00 152.66
2018-06-30 158.19 0.00 153.76
2018-03-31 165.70 0.00 155.84
2017-12-31 52.29 0.00 59.50
2017-09-30 61.37 0.00 73.55
2017-06-30 18.58 0.00 31.25
2017-03-31 29.56 0.00 30.91
2016-12-31 29.56 0.00 30.91
2015-12-31 43.05 0.00 43.81
  • Menlo Therapeutics has no debt.
  • Menlo Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Menlo Therapeutics has sufficient cash runway for 2.6 years based on current free cash flow.
  • Menlo Therapeutics has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 80.8% each year.
X
Financial health checks
We assess Menlo Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Menlo Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MNLO Dividends

 What is Menlo Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Menlo Therapeutics dividends.
If you bought $2,000 of Menlo Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Menlo Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Menlo Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:MNLO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:MNLO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Menlo Therapeutics has not reported any payouts.
  • Unable to verify if Menlo Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Menlo Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Menlo Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Menlo Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Menlo Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Menlo Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MNLO Management

 What is the CEO of Menlo Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Basta
COMPENSATION $2,605,865
AGE 52
TENURE AS CEO 3.6 years
CEO Bio

Mr. Steven L. Basta, also known as Steve, has been Chairman of Viveve Medical, Inc. since January 16, 2019. He has been the Chief Executive Officer, President and Director of Menlo Therapeutics Inc. since September 2015. Mr. Basta has been Director of Viveve Medical Inc. since September 13, 2018. Mr. Basta is a Business Advisor at Spindletop Capital. Previously, he served as a Member of Executive Council and Venture Partner at the firm. Mr. Basta served as the Chief Executive Officer of AlterG, Inc. from October 2011 to August 2015. Before joining AlterG, he led several emerging biopharmaceutical and medical device companies. He served as the Chief Executive Officer of Merz Aesthetics, Inc. from November 2002 to September 2011 and served as its President from December 2000 to June 2007. From November 2002 to February 2010, he served as Chief Executive Officer of BioForm Medical, Inc. He served as Vice President of Finance and Business Development at Curis, Inc. He joined Merz Aesthetics, Inc. in December 2000. He served as the President and Chief Executive Officer of Gliatech Inc. since December 2000. Prior to joining Gliatech Inc., he served as Treasurer of Creative Biomolecules Inc. He served as Vice President of Finance and Business Development and Chief Financial Officer of Creative BioMolecules, Inc. from January 1999 to August 2000 and served as its Vice President of Corporate Development & Investor Relations from February 1997 to January 1999. He was associated with Jundt Associates from June 1996 to December 1996. From September 1990 to June 1996, he held several positions with The Immune Response Corporation, including an Executive Director of Product Development from 1994 to 1996, Program Director for an HIV research joint venture from 1992 to 1993 and Director of Investor Relations & Market Development from 1991 to 1992. He served as an Associate with Dillon, Read & Co, Inc. from 1988 to 1990, where he began his career. He served as a Director of RF Surgical Systems, Inc from December 2013 to August 2015. He served as a Director of Carbylan Therapeutics, Inc., since September 2009 to November 2016. He served as a Director of Merz Aesthetics, Inc. since November 2002, AlterG, Inc. from November 2002 to September 7, 2015 and Gliatech Inc. since February 2001. He served as Director of KalVista Pharmaceuticals, Inc until November 22, 2016. Mr. Basta received a B.A. in Bio Medical Engineering from The Johns Hopkins University and an MBA from the Kellogg Graduate School of Business at Northwestern University.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Menlo Therapeutics management team in years:

2.1
Average Tenure
53
Average Age
  • The tenure for the Menlo Therapeutics management team is about average.
Management Team

Steve Basta

TITLE
President
COMPENSATION
$3M
AGE
52
TENURE
3.6 yrs

Kristine Ball

TITLE
Senior VP of Corporate Strategy & CFO
COMPENSATION
$1M
AGE
46
TENURE
1.6 yrs

Mary Spellman

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
56
TENURE
1.7 yrs

Paul Kwon

TITLE
Chief Scientific Officer
COMPENSATION
$645K
AGE
47
TENURE
3.3 yrs

Stuart Sedlack

TITLE
Vice President of Business Development
AGE
53

Xiaoming Zhang

TITLE
Senior Vice President of Non-Clinical & Pharmaceutical Development
AGE
54
TENURE
3.4 yrs

Danine Summers

TITLE
Senior Vice President of Medical Affairs
AGE
60
TENURE
2.1 yrs

Karen Smith

TITLE
Senior Vice President of Commercial Development
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Menlo Therapeutics board of directors in years:

3.2
Average Tenure
52
Average Age
  • The tenure for the Menlo Therapeutics board of directors is about average.
Board of Directors

Steve Basta

TITLE
President
COMPENSATION
$3M
AGE
52
TENURE
3.6 yrs

Ted Ebel

TITLE
Independent Director
COMPENSATION
$57K
AGE
48
TENURE
5.1 yrs

Scott Whitcup

TITLE
Independent Director
COMPENSATION
$45K
AGE
59
TENURE
3.2 yrs

Davie McGirr

TITLE
Independent Director
COMPENSATION
$62K
AGE
64
TENURE
1.4 yrs

Sonja Ständer

TITLE
Member of Scientific Advisory Board

Jonathan Wilkin

TITLE
Member of Scientific Advisory Board

Martin Steinhoff

TITLE
Member of Scientific Advisory Board

Jean Tang

TITLE
Member of Scientific Advisory Board

Gil Yosipovitch

TITLE
Member of Scientific Advisory Board

Aaron Royston

TITLE
Independent Director
COMPENSATION
$41K
AGE
33
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
26. Jul 18 Sell Presidio Partners Company 24. Jul 18 24. Jul 18 -500,000 $7.65 $-3,825,000
X
Management checks
We assess Menlo Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Menlo Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MNLO News

Simply Wall St News

How Financially Strong Is Menlo Therapeutics Inc. (NASDAQ:MNLO)?

(NASDAQ:MNLO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … While MNLO has no debt on its balance sheet, it doesn’t necessarily mean it exhibits financial strength. … Is MNLO right in choosing financial flexibility over lower cost of capital.

Simply Wall St -

What You Must Know About Menlo Therapeutics Inc's (NASDAQ:MNLO) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is MNLO growing fast enough to value financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Menlo Therapeutics Inc (NASDAQ:MNLO): Is Breakeven Near?

Menlo Therapeutics Inc's (NASDAQ:MNLO):. … Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. … Many investors are wondering the rate at which MNLO will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Does Menlo Therapeutics Inc's (NASDAQ:MNLO) Past Performance Indicate A Weaker Future?

Assessing Menlo Therapeutics Inc's (NASDAQ:MNLO) past track record of performance is a useful exercise for investors. … View our latest analysis for Menlo Therapeutics How Did MNLO's Recent Performance Stack Up Against Its Past? … For Menlo Therapeutics, its latest earnings (trailing twelve month) is -US$29.08M, which, against the prior year's figure, has become more negative.

Simply Wall St -

MNLO Company Info

Description

Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Details
Name: Menlo Therapeutics Inc.
MNLO
Exchange: NasdaqGS
Founded: 2011
$168,854,415
23,258,184
Website: http://www.menlotherapeutics.com
Address: Menlo Therapeutics Inc.
200 Cardinal Way,
2nd Floor,
Redwood City,
California, 94063,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS MNLO Common Stock Nasdaq Global Select US USD 25. Jan 2018
Number of employees
Current staff
Staff numbers
43
Menlo Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 01:01
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.